Biocon share price gained 2.61 per cent at Rs 398 a piece on the BSE in Thursday’s intraday trade. This came after the ...

India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...

Biocon stock price is poised for a fresh breakout from its consolidation range of 320-395, following nearly three and a half ...

Biocon advanced 2.41% to Rs 397.20 after its board is scheduled to meet on Monday, 27 January 2025, to consider and approve the raising of funds on a private placement basis.

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

Bajaj Finserv Ltd. has garnered multiple buy recommendations from various analysts, all predicting an upward movement in the ...

The market may extend its upward journey, but sustainability is the key to watch, given the elevated volatility. Below are ...

Biocon's chairperson urges India's government to exempt cancer and chronic disease drugs from taxes to alleviate patient ...

Biocon shares increased by 4.5% after the US FDA classified its Malaysian insulin facilities as Voluntary Action Indicated.

China's rural healthcare gap impacts timely medical response; the EU plans to ban 'forever chemicals'; North America eases ...